Proteomics

Dataset Information

0

Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer


ABSTRACT: To understand the transcriptomic, genomic and proteomics changes between HER2 overexpressingcells and those that have become resistant to lapatinib

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Breast

DISEASE(S): Breast Cancer

SUBMITTER: Vinothini Rajeeve  

LAB HEAD: Professor Pedro Cutillas

PROVIDER: PXD056848 | Pride | 2025-11-17

REPOSITORIES: Pride

altmetric image

Publications

Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer.

Steggall J J   Rajeeve V V   Al-Subaie N N   Naeem A A   Ikram A A   Naeem A A   Hayat A A  

British journal of cancer 20250913 10


<h4>Introduction</h4>Drug resistance is a major obstacle to the long-term effectiveness of cancer therapies. Approximately 70% of breast cancer patients relapse after 5 years of treatment, and the lack of biomarkers associated with drug resistance translates to poor prognosis in the clinic. Previous research has utilised omics approaches to uncover biomarkers driving drug resistance, with a strong emphasis on genetic mutations.<h4>Methods</h4>Here, we identified a nine-marker signature associate  ...[more]

Similar Datasets

2025-05-08 | PXD058908 | Pride
2023-06-21 | PXD039241 | Pride
2025-08-11 | PXD062506 | Pride
2025-09-29 | PXD060854 | Pride
2023-05-10 | PXD038984 | Pride
2025-01-20 | PXD051609 | Pride
2025-09-29 | PXD060852 | Pride
2025-05-14 | PXD060246 | Pride
2022-10-17 | PXD035694 | Pride
2024-09-11 | PXD053844 | Pride